Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Eneida R. Nemecek(Oregon Health & Science University), H. Joachim Deeg(Fred Hutch Cancer Center), Brent L. Wood(University of Southern California), Mary E.D. Flowers(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Eileen Sickle(Fred Hutch Cancer Center), John M. Pagel(University of Washington), Ann E. Woolfrey(University of Washington), Katherine A. Guthrie, K Doney(University of Washington Medical Center), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Antonio Bedalov(Fred Hutch Cancer Center), Bart L. Scott(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Richard T. Maziarz(Oregon Health & Science University), Jean E. Sanders(Carolinas Medical Center), Tibor Kovacsovics(Hôpital Edouard Herriot), Ralf A. Hilger(West Cancer Center), Robert P. Witherspoon(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Mohamed L. Sorror(University of Washington Medical Center)
Cited by 100
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k